In the phase 3 ENESTPath trial, 239 patients with CML in stable deep molecular response on nilotinib after imatinib were randomised to stop after 2 vs 3 years; treatment-free remission at 12 months did not differ (31.9% vs 37.5%; p=0.383).
RCTn = 239
Rea et al. Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results